....Zeltia plans to submit Yondelis for the treatment of ovarian cancer to the European Medicines Agency between mid-November and mid-December.
If Yondelis is approved for ovarian cancer treatment, the drug will have a sales potential of 1 billion euros a year, a target which the company hopes to reach by 2012. (Reporting by Tracy Rucinski; Editing by Chris Wickham) ....